Crow Point Partners’s Foamix Pharmaceuticals FOMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
$341K Buy
103,816
+16,343
+19% +$52K 0.53% 40
2019
Q3
$269K Buy
87,473
+49,053
+128% +$138K 0.04% 94
2019
Q2
$91K Buy
+38,420
New +$115K 0.01% 121

Other funds holding FOMX

Crow Point Partners's FOMX Position: Q4 2019 in Review

Crow Point Partners increased its Foamix Pharmaceuticals (FOMX) stake by 19% in Q4 2019, buying an estimated $52K and bringing the position to 103,816 shares worth $341K. The position accounts for 0.53% of the portfolio, ranked #40.

Crow Point Partners first reported a position in FOMX in Q2 2019 and has held it in 3 quarters since. 65 funds tracked by Wall St. Rank hold FOMX as of Q4 2019.

  • Crow Point Partners held 103,816 shares of Foamix Pharmaceuticals worth $341K as of Q4 2019.
  • Crow Point Partners bought 16,343 Foamix Pharmaceuticals shares in Q4 2019, an estimated $52K.
  • Foamix Pharmaceuticals made up 0.53% of Crow Point Partners's portfolio in Q4 2019, its #40 holding.
  • Crow Point Partners first reported a position in Foamix Pharmaceuticals in Q2 2019 and has held it in 3 quarters since.
  • 65 funds tracked by Wall St. Rank held Foamix Pharmaceuticals as of Q4 2019.

Based on Crow Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.